165 related articles for article (PubMed ID: 35931342)
1. Characterization of Reference Materials for TPMT and NUDT15: A GeT-RM Collaborative Project.
Pratt VM; Wang WY; Boone EC; Broeckel U; Cody N; Edelmann L; Gaedigk A; Lynnes TC; Medeiros EB; Moyer AM; Mitchell MW; Scott SA; Starostik P; Turner A; Kalman LV
J Mol Diagn; 2022 Oct; 24(10):1079-1088. PubMed ID: 35931342
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Reference Materials for CYP3A4 and CYP3A5: A (GeT-RM) Collaborative Project.
Gaedigk A; Boone EC; Turner AJ; van Schaik RHN; Chernova D; Wang WY; Broeckel U; Granfield CA; Hodge JC; Ly RC; Lynnes TC; Mitchell MW; Moyer AM; Oliva J; Kalman LV
J Mol Diagn; 2023 Sep; 25(9):655-664. PubMed ID: 37354993
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Reference Materials with an Association for Molecular Pathology Pharmacogenetics Working Group Tier 2 Status: CYP2C9, CYP2C19, VKORC1, CYP2C Cluster Variant, and GGCX: A GeT-RM Collaborative Project.
Pratt VM; Turner A; Broeckel U; Dawson DB; Gaedigk A; Lynnes TC; Medeiros EB; Moyer AM; Requesens D; Vetrini F; Kalman LV
J Mol Diagn; 2021 Aug; 23(8):952-958. PubMed ID: 34020041
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Reference Materials for Genetic Testing of CYP2D6 Alleles: A GeT-RM Collaborative Project.
Gaedigk A; Turner A; Everts RE; Scott SA; Aggarwal P; Broeckel U; McMillin GA; Melis R; Boone EC; Pratt VM; Kalman LV
J Mol Diagn; 2019 Nov; 21(6):1034-1052. PubMed ID: 31401124
[TBL] [Abstract][Full Text] [Related]
5. Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes: A GeT-RM Collaborative Project.
Pratt VM; Everts RE; Aggarwal P; Beyer BN; Broeckel U; Epstein-Baak R; Hujsak P; Kornreich R; Liao J; Lorier R; Scott SA; Smith CH; Toji LH; Turner A; Kalman LV
J Mol Diagn; 2016 Jan; 18(1):109-23. PubMed ID: 26621101
[TBL] [Abstract][Full Text] [Related]
6. Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project.
Pratt VM; Zehnbauer B; Wilson JA; Baak R; Babic N; Bettinotti M; Buller A; Butz K; Campbell M; Civalier C; El-Badry A; Farkas DH; Lyon E; Mandal S; McKinney J; Muralidharan K; Noll L; Sander T; Shabbeer J; Smith C; Telatar M; Toji L; Vairavan A; Vance C; Weck KE; Wu AH; Yeo KT; Zeller M; Kalman L
J Mol Diagn; 2010 Nov; 12(6):835-46. PubMed ID: 20889555
[TBL] [Abstract][Full Text] [Related]
7. Impact of NUDT15 genetics on severe thiopurine-related hematotoxicity in patients with European ancestry.
Schaeffeler E; Jaeger SU; Klumpp V; Yang JJ; Igel S; Hinze L; Stanulla M; Schwab M
Genet Med; 2019 Sep; 21(9):2145-2150. PubMed ID: 30728528
[TBL] [Abstract][Full Text] [Related]
8. Predictive role of NUDT15 variants on thiopurine-induced myelotoxicity in Asian inflammatory bowel disease patients.
Sutiman N; Chen S; Ling KL; Chuah SW; Leong WF; Nadiger V; Tjai M; Choon Kong CS; Schwender BJ; Chan W; Shim HH; Lim WC; Khor CC; Cheung YB; Chowbay B
Pharmacogenomics; 2018 Jan; 19(1):31-43. PubMed ID: 29210335
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetic determinants of thiopurines in an Indian cohort.
Naushad SM; Janaki Ramaiah M; Kutala VK; Hussain T; Alrokayan SA
Pharmacol Rep; 2021 Feb; 73(1):278-287. PubMed ID: 32935219
[TBL] [Abstract][Full Text] [Related]
10. Genotyping NUDT15*3 rs1166855232 reveals higher frequency of potential adverse effects of thiopurines in Natives and Mestizos from Mexico.
Texis T; Guzmán-Cruz C; Rodríguez-Dorantes M; Sánchez-García S; Mino-León D; Gonzalez-Covarrubias V
Pharmacol Rep; 2022 Feb; 74(1):257-262. PubMed ID: 34091879
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive characterization of pharmacogenetic variants in TPMT and NUDT15 in children with acute lymphoblastic leukemia.
Moriyama T; Yang W; Smith C; Pui CH; Evans WE; Relling MV; Bhatia S; Yang JJ
Pharmacogenet Genomics; 2022 Feb; 32(2):60-66. PubMed ID: 34412101
[TBL] [Abstract][Full Text] [Related]
12. A direct sequencing assay for pharmacogenetic testing of thiopurine-intolerant NUDT15 alleles in an Asian population.
Poon KS; Imran IIB; Chew SK; Tan P; Tan KM
BMC Res Notes; 2022 Apr; 15(1):148. PubMed ID: 35468862
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogeomic implications of population diversity in Latin America: TPMT and NUDT15 polymorphisms and thiopurine dosing.
Suarez-Kurtz G; Araújo GS; de Sousa SJ
Pharmacogenet Genomics; 2020 Jan; 30(1):1-4. PubMed ID: 31651720
[TBL] [Abstract][Full Text] [Related]
14. TPMT and NUDT15 Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase.
Pratt VM; Cavallari LH; Fulmer ML; Gaedigk A; Hachad H; Ji Y; Kalman LV; Ly RC; Moyer AM; Scott SA; van Schaik RHN; Whirl-Carrillo M; Weck KE
J Mol Diagn; 2022 Oct; 24(10):1051-1063. PubMed ID: 35931343
[TBL] [Abstract][Full Text] [Related]
15. Comparison of
Wang HH; He Y; Wang HX; Liao CL; Peng Y; Tao LJ; Zhang W; Yang HX
World J Gastroenterol; 2018 Feb; 24(8):941-948. PubMed ID: 29491687
[TBL] [Abstract][Full Text] [Related]
16. TPMT and NUDT15 Variants Predict Discontinuation of Azathioprine for Myelotoxicity in Patients with Inflammatory Disease: Real-World Clinical Results.
Dickson AL; Daniel LL; Zanussi J; Dale Plummer W; Wei WQ; Liu G; Reese T; Anandi P; Birdwell KA; Kawai V; Cox NJ; Dupont WD; Hung AM; Feng Q; Stein CM; Chung CP
Clin Pharmacol Ther; 2022 Jan; 111(1):263-271. PubMed ID: 34582038
[TBL] [Abstract][Full Text] [Related]
17. The effects of
Nghia H; Than HH; Dong CV; Oanh TTK; Truc VTT; Ngan CTT; Ngon HT; Binh NT; Dung PC; Anh Vu H; Xinh PT
Pediatr Hematol Oncol; 2022 Sep; 39(6):561-570. PubMed ID: 35156873
[TBL] [Abstract][Full Text] [Related]
18.
Yang J; Wang P; Qin Z; Jia M; Zhang C; Tian X; Zheng Y; Zhang A; Zhang X; Liu S
Genet Test Mol Biomarkers; 2019 Oct; 23(10):751-757. PubMed ID: 31556692
[No Abstract] [Full Text] [Related]
19. NUDT15: A bench to bedside success story.
Moyer AM
Clin Biochem; 2021 Jun; 92():1-8. PubMed ID: 33675810
[TBL] [Abstract][Full Text] [Related]
20. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update.
Relling MV; Schwab M; Whirl-Carrillo M; Suarez-Kurtz G; Pui CH; Stein CM; Moyer AM; Evans WE; Klein TE; Antillon-Klussmann FG; Caudle KE; Kato M; Yeoh AEJ; Schmiegelow K; Yang JJ
Clin Pharmacol Ther; 2019 May; 105(5):1095-1105. PubMed ID: 30447069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
